Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

Thierry Le Chevalier, D. Brisgand, Jean‐Yves Douillard et al. · Journal of Clinical Oncology · 1994 · 823 citations

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

G. Dark, S A Hill, Vivien E. Prise et al. · PubMed · 1997 · 624 citations

Vascular Shutdown, Tumor Biology, Oncology +16

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

P. Fumoleau, F.M. Delgado, T. Delozier et al. · Journal of Clinical Oncology · 1993 · 327 citations

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

G. M. Tozer, Vivien E. Prise, John Wilson et al. · PubMed · 1999 · 324 citations

Quantitative Autoradiography, Pathology, Tumor Biology +19

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

Konstantina Grosios, S E Holwell, Andrew McGown et al. · British Journal of Cancer · 1999 · 213 citations · Full text